BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 11807015)

  • 1. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
    Chakraverty R; Peggs K; Chopra R; Milligan DW; Kottaridis PD; Verfuerth S; Geary J; Thuraisundaram D; Branson K; Chakrabarti S; Mahendra P; Craddock C; Parker A; Hunter A; Hale G; Waldmann H; Williams CD; Yong K; Linch DC; Goldstone AH; Mackinnon S
    Blood; 2002 Feb; 99(3):1071-8. PubMed ID: 11807015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; Mackinnon S
    Blood; 2000 Oct; 96(7):2419-25. PubMed ID: 11001893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
    Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
    Kröger N; Sayer HG; Schwerdtfeger R; Kiehl M; Nagler A; Renges H; Zabelina T; Fehse B; Ayuk F; Wittkowsky G; Schmitz N; Zander AR
    Blood; 2002 Dec; 100(12):3919-24. PubMed ID: 12393448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
    Marks DI; Lush R; Cavenagh J; Milligan DW; Schey S; Parker A; Clark FJ; Hunt L; Yin J; Fuller S; Vandenberghe E; Marsh J; Littlewood T; Smith GM; Culligan D; Hunter A; Chopra R; Davies A; Towlson K; Williams CD
    Blood; 2002 Nov; 100(9):3108-14. PubMed ID: 12384406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
    Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
    Pérez-Simón JA; Kottaridis PD; Martino R; Craddock C; Caballero D; Chopra R; García-Conde J; Milligan DW; Schey S; Urbano-Ispizua A; Parker A; Leon A; Yong K; Sureda A; Hunter A; Sierra J; Goldstone AH; Linch DC; San Miguel JF; Mackinnon S;
    Blood; 2002 Nov; 100(9):3121-7. PubMed ID: 12384408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
    Mead AJ; Thomson KJ; Morris EC; Mohamedbhai S; Denovan S; Orti G; Fielding AK; Kottaridis PD; Hough R; Chakraverty R; Linch DC; Mackinnon S; Peggs KS
    Blood; 2010 Jun; 115(25):5147-53. PubMed ID: 20371745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
    Rodriguez R; Parker P; Nademanee A; Smith D; O'Donnell MR; Stein A; Snyder DS; Fung HC; Krishnan AY; Popplewell L; Cohen S; Somlo G; Angelopoulou M; Al-Kadhimi Z; Falk PM; Spielberger R; Kogut N; Sahebi F; Senitzer D; Slovak M; Schriber J; Forman SJ
    Bone Marrow Transplant; 2004 Jun; 33(11):1123-9. PubMed ID: 15064696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
    Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
    Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
    Van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Hoffman R; Sossman J
    Bone Marrow Transplant; 2003 Sep; 32(5):471-6. PubMed ID: 12942092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
    Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
    Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.
    Inamoto Y; Oba T; Miyamura K; Terakura S; Tsujimura A; Kuwatsuka Y; Tokunaga M; Kasai M; Murata M; Naoe T; Kodera Y
    Int J Hematol; 2006 May; 83(4):356-62. PubMed ID: 16757439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
    Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.
    Loren AW; Luger SM; Stadtmauer EA; Tsai DE; Schuster S; Nasta SD; Goldstein SC; Perl A; Orloff G; Oliver JC; Green J; Emerson SG; Porter DL
    Bone Marrow Transplant; 2005 May; 35(9):921-6. PubMed ID: 15765118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.